Orlistat (CAS 96829-58-2) is a high-purity pharmaceutical API classified as a selective lipase inhibitor, featuring a synthetic lipophilic molecular structure designed to target pancreatic and gastric lipases. Unlike central-acting weight loss agents, it acts locally in the gastrointestinal tract—irreversibly inhibiting fat digestion by blocking lipase-mediated breakdown of triglycerides into absorbable fatty acids. This mechanism reduces dietary fat absorption by up to 30% without affecting carbohydrate or protein metabolism, supporting gradual, sustainable weight management.
It caters to the core needs of pharmaceutical manufacturers, weight management product developers, and healthcare supplement brands. Clinically validated for obesity and overweight management (often alongside diet and exercise), it is suitable for oral formulations like capsules and tablets. Produced under strict GMP standards, each batch undergoes rigorous purity and potency testing to meet international pharmacopoeia requirements, ensuring safety and consistency for clinical use. For businesses prioritizing evidence-based, non-central-acting weight loss solutions, this Orlistat API serves as a reliable raw material for developing effective, well-tolerated weight management medications.
